Locus Cell Co., Ltd. (6891) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Locus Cell Co., Ltd. (6891:TWSE), powered by AI.

Current Price
$44.70
P/E Ratio
11.9
Market Cap
2.3B
Sector
Unknown
What is the Locus Cell Co., Ltd. stock price forecast?

Locus Cell Co., Ltd. is currently trading at $44.70. View real-time AI analysis on Alpha Lenz.

What is Locus Cell Co., Ltd. insider trading activity?

View the latest insider trading data for Locus Cell Co., Ltd. on Alpha Lenz.

What is Locus Cell Co., Ltd.'s P/E ratio?

Locus Cell Co., Ltd.'s P/E ratio is 11.9.

Locus Cell Co., Ltd.

TWSE · 6891
NT$44.70-1.35(-2.93%)
Ask about Locus Cell Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Locus Cell Co., Ltd. trades at a P/E of 11.9 (undervalued) with strong ROE of 45.0%. 3Y revenue CAGR of 31.0% highlights clear growth momentum.

Ask for details

Company Overview

Locus Cell Co., Ltd. is a biotechnology and pharmaceutical company headquartered in New Taipei City, Taiwan. Specializing in cell therapy, the company focuses on the entrusted development and manufacturing of cell therapy-related products, serving the burgeoning life sciences tools and services sector. Founded in 2020, Locus Cell plays a role in advancing medical research and innovation in bio-therapeutic drugs, targeting critical healthcare challenges through next-generation biotechnologies. The company’s business model supports the pharmaceutical and medical research industries, collaborating on therapeutic developments that potentially address complex diseases. With a dynamic growth trajectory and increasing revenues, Locus Cell has positioned itself as a key participant in Taiwan’s biotechnology landscape, contributing to the region’s status as an innovation hub within Asia’s life sciences market. The company’s operations and output help accelerate the translation of cell-based technologies from the research stage toward clinical and commercial applications, underscoring its importance in the supply chain of cell therapy and regenerative medicine sectors.

SectorUnknown
IndustryUnknown
0

Company Statistics

FY 2021

Profile

NT$2.27BMarket Cap
NT$1.40BRevenue
0.00Shares Out
0Employees

Margins

25.81%Gross
16.43%EBITDA
16.24%Operating
18.32%Pre-Tax
14.57%Net

Valuation

11.91P/E
4.49P/B
1.62EV/Sales
11.12EV/EBITDA
-24.01P/FCF

Growth (CAGR)

31.03%Rev 3Yr
N/ARev 5Yr
44.11%Op Inc 3Yr
N/AOp Inc 5Yr
46.85%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

16.96%ROA
45.00%ROE
28.65%ROIC

Financial Health

NT$78.70MCash & Cash Equivalents
NT$371.26MNet Debt
83.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Locus Cell Co., Ltd. (ticker: 6891) is a company listed on TWSE in the Unknown sector (Unknown). Market cap is $2.3B.

The current price is 44.7 with a P/E ratio of 11.91x and P/B of 4.49x.

ROE is 45.00% and operating margin is 16.24%. Annual revenue is $1.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Locus Cell Co., Ltd. (6891) Stock Forecast 2026 $44.70 — Price, Financials & Analyst Targets | Alpha Lenz